logo

Alnylam Pharmaceuticals Inc. (ALNY)



Trade ALNY now with
  Date
  Headline
6/20/2018 7:01:28 AM Alnylam Pharma Appoints Masako Nakamura As SVP, Head Of Asia, And Jing Marantz As SVP, Head Of Medical Affairs
6/8/2018 7:03:18 AM Alnylam Reports Updated Positive Results From Phase 1/2 Study Of Lumasiran In Patients With Primary Hyperoxaluria Type 1
6/4/2018 7:02:30 AM Alnylam Receives Orphan Drug Designation From FDA For ALN-TTRsc02
5/15/2018 7:02:27 AM Alnylam Appoints Colleen Reitan To The Board Of Directors
5/8/2018 7:06:29 AM Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery Of RNAi Therapeutics
5/3/2018 4:02:10 PM Alnylam Pharma Q1 Non-GAAP Loss Per Share $1.22 Vs Loss $1.06 Last Year
5/3/2018 7:04:55 AM Alnylam Achieves Alignment With FDA On Accelerated Development Path For Lumasiran
4/24/2018 7:02:35 AM Alnylam Reports New Clinical Results From The APOLLO Phase 3 Study Of Patisiran At AAN 2018 Annual Meeting
4/23/2018 7:02:22 AM Alnylam Receives Positive Opinion For Orphan Drug Designation In The European Union For ALN-TTRsc02
4/20/2018 2:13:35 PM Alnylam Reaches Settlement Agreement With Dicerna Pharmaceuticals